Sanofi Adds LeGoo® To Its Biosurgery Portfolio With Pluromed Acquisition

In short

Sanofi and Pluromed Inc. have announced that  they  have  entered  into  a  definitive  agreement  under  which  European healthcare giant Sanofi  is  to acquire  Pluromed  Inc., a  medical  device  company  based  in  Woburn,  Massachusetts. Last year Sanofi acquired Genzyme corporation, and this new announcement further signals its intent in the biosurgery space.

Full details of the transaction have not been announced at this time.

Background

Sanofi’s Biosurgery division develops and markets innovative, biologically based  products  for  osteoarthritis  relief,  adhesion  prevention,  cartilage  repair,  and  severe  burn  treatment. Following its 2011 acquisition of Genzyme Corporation, many of Sanofi Biosurgery’s products will be familiar names to medical professionals who treat articular cartilage defects(Synvisc®, Synvisc-One™ (hylan G-F 20), Carticel® (autologous cultured chondrocytes),  MACI® (Matrix-induced  Autologous  Chondrocyte  Implantation)), or who use anti-post-surgical adhesion products (Seprafilm®).

Pluromed  has  developed  a  proprietary  polymer  technology,  called  Rapid  Transition  Polymers (RTP™),  pioneering the  use  of  injectable  plugs to  improve  the safety,  efficacy  and  economics of medical  interventions.

LeGoo® is a thermo-sensitive, biocompatible and non-toxic liquid gel that forms a plug  when injected into a blood vessel to  temporarily  stop  blood  flow.  The  plug  dissolves  rapidly  via  cooling  or  spontaneously  after several  minutes. Once  dissolved, the residue is of sufficiently low a concentration that plug reformation is not a risk. According to the company, in  a prospective, randomized study, LeGoo® has been shown to provide better operating conditions than conventional occlusion techniques, by limiting blood flow into a surgical field without causing damage to the vessels. The study also showed a reduction in the time required to perform an anastomosis for beating heart surgery when using LeGoo®.

The product, intended for temporary endovascular occlusion of blood vessels during surgical procedures, has been in the European market for a few years and gained FDA approval for use on vessels up to 4mm diameter, as announced on our site last October here.

Company comments
“The  acquisition  of  Pluromed  underscores  Sanofi’s  commitment  to  strengthen  its  Biosurgery portfolio,”  said  Alison  Lawton,  Senior  Vice  President  and  General  Manager,  Sanofi  Biosurgery. “LeGoo® is a breakthrough technology with the potential to change the paradigm of vascular and cardiovascular surgical procedures, by providing fast, temporary control of blood flow while avoiding vessel trauma associated with standard of care.”

“The  synergies  between  our  companies  were  clear  from  the  beginning,”  said  Jean-Marie  Vogel, Chief  Executive  Officer  of  Pluromed,  Inc.  “We  are  confident  that  Sanofi  has  the  expertise  and resources necessary to bring LeGoo® to market and drive adoption.”

Clinician (Director) comments
“LeGoo®represents a major advancement in surgical technology because of its ability to control bleeding without clamps or snares that can injure delicate blood vessels,” said Dr. William E. Cohn, Director, Minimally Invasive Surgical Technology at the  Texas Heart Institute in Houston and a member of Pluromed’s Board of Directors. “This breakthrough gives surgeons a way to temporarily stop blood flow into the surgical field, which is imperative for clear visualization and accurate placement of sutures. I believe this technology will be widely adopted in cardiovascular surgery and perhaps in other fields in the future.”

Source: Sanofi